Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer

Published:2019-03 Issue:2 Volume:25 Page:73-79
ISSN:1540-336X
Container-title:The Cancer Journal
language:en
Short-container-title:Cancer J

Author:

Seeber Andreas,Chahine Georges,Nasr Fadi,Dean Andrew,Miranova Mira,Jameson Gayle,Robert Nicholas,Gastl Guenther,Zwierzina Heinz

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference33 articles.

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group;Lancet,1998

2. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer;J Clin Oncol,2004

3. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment;J Clin Oncol,1998

4. Progression-free survival decreases with each subsequent therapy in patients presenting for phase I clinical trials;J Cancer,2012

5. Late lines of treatment benefit survival in metastatic breast cancer in current practice?;Breast,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2;JCO Precision Oncology;2023-04

2. The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: Current and future perspectives;Gynecologic Oncology Reports;2022-08

3. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice;Bulletin du Cancer;2020-04

4. Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?;JNCI: Journal of the National Cancer Institute;2019-12-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3